

CANCER VACCINES: TECHNOLOGIES AND GLOBAL MARKETS



PHM173A
January 2015

Shalini Shahani Dewan
Project Analyst

ISBN: 1-62296-008-4



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
CONTRIBUTIONS OF THE STUDY AND FOR WHOM	2
SCOPE OF THE STUDY	3
METHODOLOGY	3
INFORMATION SOURCES	3
ANALYSTS' CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2012-2019 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	10
DEFINITIONS	10
HISTORY OF CANCER AND ITS MANAGEMENT	11
<i>TABLE 1 HISTORY OF CANCER AND ITS MANAGEMENT</i>	12
CLASSIFICATION OF CANCERS	13
CLASSIFICATION BY SITE OF ORIGIN	13
CLASSIFICATION BY TISSUE TYPE	13
Carcinoma	14
Adenocarcinoma	14
Squamous Cell Carcinoma	14
Sarcomas	14
Myeloma	14
Leukemias	15
Lymphomas	15
Mixed Types	15
CLASSIFICATION BY GRADE	15
SYMPTOMS OF CANCER	15
LOCAL SYMPTOMS	16
SYSTEMIC SYMPTOMS	16
SYMPTOMS OF THE SPREAD OF CANCER OR METASTASIS	16
RISK FACTORS	16
CANCER-CAUSING AGENTS	16
CHEMICAL CARCINOGENS	17
IONIZING RADIATION	17
VIRAL AND BACTERIAL INFECTIONS	17
GENETIC OR INHERITED CANCERS	17
HORMONAL CHANGES	17
IMMUNE SYSTEM DYSFUNCTION	17

TOPIC	PAGE NO.
COMMERCIALLY AVAILABLE CANCER VACCINES	18
LIVER CANCER	18
PROSTATE CANCER	20
Radical Retropubic Prostatectomy	20
Laparoscopic Prostatectomy	20
Radical Perineal Prostatectomy	20
Transurethral Resection of the Prostate	20
CERVICAL CANCER	21
PREVALENCE	22
<i>TABLE 2 ESTIMATED GLOBAL INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE OF CANCER, 2012 (THOUSANDS)</i>	23
INCIDENCE AND MORTALITY RATE	23
<i>TABLE 3 GLOBAL INCIDENCE AND MORTALITY RATES OF CANCER, 2012</i>	23
CANCER STATISTICS BY GEOGRAPHY	23
<i>TABLE 4 ESTIMATED U.S. INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012</i>	23
<i>TABLE 5 ESTIMATED EUROPEAN UNION INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012</i>	24
GLOBAL CANCER STATISTICS BY TYPE OF CANCER	24
<i>TABLE 6 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN BOTH SEXES, 2012 (IN NUMBERS)</i>	25
<i>TABLE 7 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN MEN, 2012 (IN NUMBERS)</i>	25
<i>TABLE 8 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN WOMEN, 2012 (IN NUMBERS)</i>	26
VARIOUS FORMS OF CANCER STATISTICS BY GEOGRAPHY	26
<i>TABLE 9 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN THE U.S., 2012</i>	26
<i>TABLE 10 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN EUROPE, 2012</i>	27
<i>TABLE 11 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN ASIA, 2012</i>	28
CANCER AND THE IMMUNE SYSTEM	28
MOLECULAR BIOLOGY OF CANCER	28
CANCER PATHOPHYSIOLOGY	29
ONCOGENES	29
TUMOR SUPPRESSOR GENES	29
PREVENTION OF CANCER	30
MANAGEMENT OF CANCER	30
SURGERY	30
CHEMOTHERAPY	31
RADIATION THERAPY	31
TARGETED THERAPY	31
IMMUNOTHERAPY	31
HORMONAL THERAPY	31
BIOLOGICAL THERAPY	31
CANCER VACCINES	32
CLASSIFICATION OF CANCER VACCINES	32
Preventive (or Prophylactic) Vaccines	32

TOPIC	PAGE NO.
Therapeutic Vaccines	32
MANUFACTURING/CREATING VACCINES	33
TYPES OF CANCER VACCINES	33
Tumor Cell Vaccines	33
Cancer Stem Cell Vaccines	34
Peptide/Protein Vaccines	34
Antigen Vaccines	34
Anti-idiotypic Vaccines	35
Heat Shock Protein Vaccines	35
DNA and Vector-Based Vaccines	35
CHAPTER 4 REGULATORY ASPECTS	38
REGULATORY HISTORY OF APPROVED CANCER VACCINES	38
TABLE 12 REGULATORY APPROVALS OF CANCER VACCINES, THROUGH JULY 2014	39
RECALLS	40
TABLE 13 PRODUCT RECALLS, JAN. 2010 TO JULY 2014	40
ORPHAN DRUG DESIGNATION	41
TABLE 14 SIGNIFICANT ORPHAN DRUG DESIGNATIONS APPROVED FROM JAN. 2010 TO JULY 2014	41
OTHER SIGNIFICANT REGULATORY ASPECTS	42
CHAPTER 5 NEW DEVELOPMENTS	44
PROSTATE CANCER	45
TABLE 15 CLINICAL TRIALS FOR PROSTATE CANCER VACCINES (NO.)	45
TABLE 16 SIGNIFICANT PROSTATE CANCER VACCINES IN DEVELOPMENT	46
BREAST CANCER	47
TABLE 17 CLINICAL TRIALS FOR BREAST CANCER VACCINES (NO.)	47
TABLE 18 SIGNIFICANT BREAST CANCER VACCINES IN DEVELOPMENT	47
CERVICAL CANCER	48
TABLE 19 CLINICAL TRIALS FOR CERVICAL CANCER VACCINES (NO.)	49
TABLE 20 SIGNIFICANT CERVICAL CANCER VACCINES IN DEVELOPMENT	49
LIVER CANCER	50
TABLE 21 CLINICAL TRIALS FOR LIVER CANCER VACCINES (NO.)	51
TABLE 22 SIGNIFICANT LIVER CANCER VACCINES IN DEVELOPMENT	51
LUNG CANCER	52
TABLE 23 CLINICAL TRIALS FOR LUNG CANCER VACCINES (NO.)	52
TABLE 24 SIGNIFICANT VACCINES IN DEVELOPMENT FOR LUNG CANCER	53
STOMACH CANCER	53
TABLE 25 CLINICAL TRIALS FOR STOMACH CANCER VACCINES (NO.)	54
TABLE 26 SIGNIFICANT STOMACH CANCER VACCINES IN DEVELOPMENT	54
COLORECTAL CANCER	55
TABLE 27 CLINICAL TRIALS FOR COLORECTAL CANCER VACCINES (NO.)	55
TABLE 28 SIGNIFICANT COLORECTAL CANCER VACCINES IN DEVELOPMENT	56
ESOPHAGEAL CANCER	56
TABLE 29 CLINICAL TRIALS FOR ESOPHAGEAL CANCER VACCINES (NO.)	57
TABLE 30 SIGNIFICANT ESOPHAGEAL CANCER VACCINES IN DEVELOPMENT	57
CHAPTER 6 MARKET ANALYSIS OF CANCER VACCINES	59

TOPIC	PAGE NO.
MARKET BY TYPE	59
MARKET OVERVIEW	59
MARKET REVENUES	60
<i>TABLE 31 GLOBAL MARKET FOR CANCER VACCINES BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	61
<i>FIGURE 1 GLOBAL MARKET FOR CANCER VACCINES BY TYPE, 2012-2019 (\$ MILLIONS)</i>	61
MARKET SHARES	62
<i>TABLE 32 GLOBAL MARKET SHARES OF CANCER VACCINES BY TYPE, 2013 (%)</i>	62
<i>FIGURE 2 GLOBAL MARKET SHARES OF CANCER VACCINES BY TYPE, 2013 (%)</i>	62
MARKET BY REGION	62
MARKET OVERVIEW	63
MARKET REVENUES	64
<i>TABLE 33 GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	64
<i>FIGURE 3 GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2012-2019 (\$ MILLIONS)</i>	64
THERAPEUTIC VACCINES	65
Market Overview	66
Market Revenues	68
<i>TABLE 34 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	69
<i>FIGURE 4 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, 2012-2019 (\$ MILLIONS)</i>	70
Market Shares	70
<i>TABLE 35 GLOBAL MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2013 (%)</i>	70
<i>FIGURE 5 GLOBAL MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2013 (%)</i>	70
PROPHYLACTIC VACCINES	71
Market Overview	71
Market Revenues	73
<i>TABLE 36 GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	74
<i>FIGURE 6 GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	74
Market Shares	75
<i>TABLE 37 GLOBAL MARKET SHARES OF PROPHYLACTIC VACCINES BY REGION, 2013 (%)</i>	75
<i>FIGURE 7 GLOBAL MARKET SHARES OF PROPHYLACTIC VACCINES BY REGION, 2013 (%)</i>	75
INDUSTRY STRUCTURE	76
PROPHYLACTIC CANCER VACCINES	76
Market Leaders	76
<i>TABLE 38 LEADING MANUFACTURERS/SUPPLIERS OF PROPHYLACTIC CANCER VACCINES, 2013</i>	77
Market Shares	77
<i>TABLE 39 GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2013 (%)</i>	77

TOPIC	PAGE NO.
<i>FIGURE 8 GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2013 (%)</i>	77
THERAPEUTIC CANCER VACCINES	78
Market Leader	78
<i>TABLE 40 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC CANCER VACCINES, 2013</i>	78
Market Share	78
<i>TABLE 41 GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2013 (%)</i>	79
<i>FIGURE 9 GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2013 (%)</i>	79
CHAPTER 7 MARKET BY CANCER TYPE	81
GLOBAL MARKET BY CANCER TYPE	81
MARKET REVENUES	81
<i>TABLE 42 GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, THROUGH 2019 (\$ MILLIONS)</i>	82
<i>FIGURE 10 GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, 2012-2019 (\$ MILLIONS)</i>	82
MARKET SHARES	82
<i>TABLE 43 GLOBAL MARKET SHARES OF CANCER VACCINES BY CANCER TYPE, 2013 (%)</i>	83
<i>FIGURE 11 GLOBAL MARKET SHARES OF CANCER VACCINES BY CANCER TYPE, 2013 (%)</i>	83
PROSTATE CANCER	83
Market Overview	83
Market Revenues	84
<i>TABLE 44 GLOBAL MARKET FOR PROSTATE CANCER VACCINES, THROUGH 2019 (\$ MILLIONS)</i>	85
<i>FIGURE 12 GLOBAL MARKET FOR PROSTATE CANCER VACCINES, 2012-2019 (\$ MILLIONS)</i>	85
LIVER CANCER	85
Market Overview	86
Market Revenues	87
<i>TABLE 45 GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	87
<i>FIGURE 13 GLOBAL MARKET FOR LIVER CANCER VACCINES, THROUGH 2019 (\$ MILLIONS)</i>	87
CERVICAL CANCER VACCINES	88
Market Overview	88
Market Revenues	89
<i>TABLE 46 GLOBAL MARKET FOR CERVICAL CANCER VACCINES, THROUGH 2019 (\$ MILLIONS)</i>	90
<i>FIGURE 14 GLOBAL MARKET FOR CERVICAL CANCER VACCINES, 2012-2019 (\$ MILLIONS)</i>	90
CHAPTER 8 PATENT ANALYSIS	92
PATENTS BY YEAR	92
<i>TABLE 47 SIGNIFICANT PATENTS BY YEAR JAN. 2010 TO JUNE 2014 (NO.)</i>	92
<i>FIGURE 15 SIGNIFICANT PATENTS BY YEAR, JAN. 2010 TO JUNE 2014 (NO.)</i>	93

TOPIC	PAGE NO.
PATENTS BY TYPE/CATEGORY	93
<i>TABLE 48 PATENTS BY CATEGORY, JAN. 2010 TO JUNE 2014 (NO.)</i>	93
<i>FIGURE 16 PATENTS BY CATEGORY, JAN. 2010 TO JUNE 2014 (NO.)</i>	93
PATENTS BY COMPANY	94
<i>TABLE 49 U.S. PATENTS BY COMPANY, JAN. 2010 TO JUNE 2014 (NO.)</i>	94
PATENTS BY PATENT HOLDER'S COUNTRY	95
<i>TABLE 50 U.S. PATENTS BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (NO.)</i>	95
<i>FIGURE 17 U.S. PATENTS BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (NO.)</i>	96
<i>TABLE 51 PATENT SHARES BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (%)</i>	96
<i>FIGURE 18 PATENT SHARES BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (%)</i>	97
PATENTS BY ASSIGNEE TYPE	97
<i>TABLE 52 PATENTS BY ASSIGNEE TYPE, JAN. 2010 TO JUNE 2014 (NO.)</i>	98
<i>FIGURE 19 PATENTS BY ASSIGNEE TYPE, JAN. 2010 TO JUNE 2014 (NO.)</i>	98
CHAPTER 9 CURRENT SITUATION	100
FACTORS AFFECTING CANCER VACCINES	100
INCREASING PREVALENCE OF CANCER	100
AGING POPULATION	101
LIFESTYLE CHANGES	101
APPROVALS FOR ADDITIONAL INDICATIONS	101
COMPETITION	101
MANUFACTURERS' STRATEGIES	101
CHAPTER 10 COMPANY PROFILES	104
ADAMIS PHARMACEUTICALS CORP.	104
ADURO BIOTECH INC.	104
ADVANTAGENE INC.	105
ADVAXIS INC.	105
ALPHAVAX HUMAN VACCINES INC.	106
ALTOR BIOSCIENCE CORP.	107
ANTIGEN EXPRESS INC.	108
BAVARIAN NORDIC A/S	108
BELLICUM PHARMACEUTICALS	109
BIOVEST INTERNATIONAL	109
CELLDEX THERAPEUTICS	110
CUREVAC GMBH	110
DENDREON	111
EMD SERONO	111
GALINA BIOPHARMA	112
GENEXINE INC.	112
GLAXOSMITHKLINE	113
GLOBEIMMUNE INC.	113
GRADALIS INC.	114
HEAT BIOLOGICS INC.	114

TOPIC	PAGE NO.
IMMUNE CELL THERAPY INC. (ICT)	115
IMMUNICUM	115
IMMUNOFRONTIER INC.	116
IMMUNOVATIVE THERAPIES LTD.	116
INOVIO PHARMACEUTICALS	117
ISA PHARMACEUTICALS	117
KAEL-GEMVAX CO. LTD.	118
MERCK & CO.	118
NEWLINK GENETICS CORP.	119
NOVARX CORP.	120
ONCOTHYREON	120
ONCOVIR INC	121
OXFORD BIOMEDICA	121
SOTIO AS	122
UBIVAC LLC	122
VICAL INC.	123
VACCINOGEN INC.	123
VAXON BIOTECH	124
CHAPTER 11 ACRONYMS	126

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2019 (\$ MILLIONS)	8
TABLE 1 HISTORY OF CANCER AND ITS MANAGEMENT	12
TABLE 2 ESTIMATED GLOBAL INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE OF CANCER, 2012 (THOUSANDS)	23
TABLE 3 GLOBAL INCIDENCE AND MORTALITY RATES OF CANCER, 2012	23
TABLE 4 ESTIMATED U.S. INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012	23
TABLE 5 ESTIMATED EUROPEAN UNION INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012	24
TABLE 6 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN BOTH SEXES, 2012 (IN NUMBERS)	25
TABLE 7 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN MEN, 2012 (IN NUMBERS)	25
TABLE 8 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN WOMEN, 2012 (IN NUMBERS)	26
TABLE 9 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN THE U.S., 2012	26
TABLE 10 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN EUROPE, 2012	27
TABLE 11 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN ASIA, 2012	28
TABLE 12 REGULATORY APPROVALS OF CANCER VACCINES, THROUGH JULY 2014	39
TABLE 13 PRODUCT RECALLS, JAN. 2010 TO JULY 2014	40
TABLE 14 SIGNIFICANT ORPHAN DRUG DESIGNATIONS APPROVED FROM JAN. 2010 TO JULY 2014	41
TABLE 15 CLINICAL TRIALS FOR PROSTATE CANCER VACCINES (NO.)	45
TABLE 16 SIGNIFICANT PROSTATE CANCER VACCINES IN DEVELOPMENT	46
TABLE 17 CLINICAL TRIALS FOR BREAST CANCER VACCINES (NO.)	47
TABLE 18 SIGNIFICANT BREAST CANCER VACCINES IN DEVELOPMENT	47
TABLE 19 CLINICAL TRIALS FOR CERVICAL CANCER VACCINES (NO.)	49
TABLE 20 SIGNIFICANT CERVICAL CANCER VACCINES IN DEVELOPMENT	49
TABLE 21 CLINICAL TRIALS FOR LIVER CANCER VACCINES (NO.)	51
TABLE 22 SIGNIFICANT LIVER CANCER VACCINES IN DEVELOPMENT	51
TABLE 23 CLINICAL TRIALS FOR LUNG CANCER VACCINES (NO.)	52
TABLE 24 SIGNIFICANT VACCINES IN DEVELOPMENT FOR LUNG CANCER	53
TABLE 25 CLINICAL TRIALS FOR STOMACH CANCER VACCINES (NO.)	54
TABLE 26 SIGNIFICANT STOMACH CANCER VACCINES IN DEVELOPMENT	54
TABLE 27 CLINICAL TRIALS FOR COLORECTAL CANCER VACCINES (NO.)	55
TABLE 28 SIGNIFICANT COLORECTAL CANCER VACCINES IN DEVELOPMENT	56
TABLE 29 CLINICAL TRIALS FOR ESOPHAGEAL CANCER VACCINES (NO.)	57
TABLE 30 SIGNIFICANT ESOPHAGEAL CANCER VACCINES IN DEVELOPMENT	57
TABLE 31 GLOBAL MARKET FOR CANCER VACCINES BY TYPE, THROUGH 2019 (\$ MILLIONS)	61
TABLE 32 GLOBAL MARKET SHARES OF CANCER VACCINES BY TYPE, 2013 (%)	62
TABLE 33 GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2019 (\$ MILLIONS)	64
TABLE 34 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, THROUGH 2019 (\$ MILLIONS)	69

TABLE HEADING	PAGE NO.
TABLE 35 GLOBAL MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2013 (%)	70
TABLE 36 GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, THROUGH 2019 (\$ MILLIONS)	74
TABLE 37 GLOBAL MARKET SHARES OF PROPHYLACTIC VACCINES BY REGION, 2013 (%)	75
TABLE 38 LEADING MANUFACTURERS/SUPPLIERS OF PROPHYLACTIC CANCER VACCINES, 2013	77
TABLE 39 GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2013 (%)	77
TABLE 40 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC CANCER VACCINES, 2013	78
TABLE 41 GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2013 (%)	79
TABLE 42 GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, THROUGH 2019 (\$ MILLIONS)	82
TABLE 43 GLOBAL MARKET SHARES OF CANCER VACCINES BY CANCER TYPE, 2013 (%)	83
TABLE 44 GLOBAL MARKET FOR PROSTATE CANCER VACCINES, THROUGH 2019 (\$ MILLIONS)	85
TABLE 45 GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, THROUGH 2019 (\$ MILLIONS)	87
TABLE 46 GLOBAL MARKET FOR CERVICAL CANCER VACCINES, THROUGH 2019 (\$ MILLIONS)	90
TABLE 47 SIGNIFICANT PATENTS BY YEAR JAN. 2010 TO JUNE 2014 (NO.)	92
TABLE 48 PATENTS BY CATEGORY, JAN. 2010 TO JUNE 2014 (NO.)	93
TABLE 49 U.S. PATENTS BY COMPANY, JAN. 2010 TO JUNE 2014 (NO.)	94
TABLE 50 U.S. PATENTS BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (NO.)	95
TABLE 51 PATENT SHARES BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (%)	96
TABLE 52 PATENTS BY ASSIGNEE TYPE, JAN. 2010 TO JUNE 2014 (NO.)	98

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2012-2019 (\$ MILLIONS)	8
FIGURE 1 GLOBAL MARKET FOR CANCER VACCINES BY TYPE, 2012-2019 (\$ MILLIONS)	61
FIGURE 2 GLOBAL MARKET SHARES OF CANCER VACCINES BY TYPE, 2013 (%)	62
FIGURE 3 GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2012-2019 (\$ MILLIONS)	64
FIGURE 4 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, 2012-2019 (\$ MILLIONS)	70
FIGURE 5 GLOBAL MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2013 (%)	70
FIGURE 6 GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, THROUGH 2019 (\$ MILLIONS)	74
FIGURE 7 GLOBAL MARKET SHARES OF PROPHYLACTIC VACCINES BY REGION, 2013 (%)	75
FIGURE 8 GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2013 (%)	77
FIGURE 9 GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2013 (%)	79
FIGURE 10 GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, 2012-2019 (\$ MILLIONS)	82
FIGURE 11 GLOBAL MARKET SHARES OF CANCER VACCINES BY CANCER TYPE, 2013 (%)	83
FIGURE 12 GLOBAL MARKET FOR PROSTATE CANCER VACCINES, 2012-2019 (\$ MILLIONS)	85
FIGURE 13 GLOBAL MARKET FOR LIVER CANCER VACCINES, THROUGH 2019 (\$ MILLIONS)	87
FIGURE 14 GLOBAL MARKET FOR CERVICAL CANCER VACCINES, 2012-2019 (\$ MILLIONS)	90
FIGURE 15 SIGNIFICANT PATENTS BY YEAR, JAN. 2010 TO JUNE 2014 (NO.)	93
FIGURE 16 PATENTS BY CATEGORY, JAN. 2010 TO JUNE 2014 (NO.)	93
FIGURE 17 U.S. PATENTS BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (NO.)	96
FIGURE 18 PATENT SHARES BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (%)	97
FIGURE 19 PATENTS BY ASSIGNEE TYPE, JAN. 2010 TO JUNE 2014 (NO.)	98